AVXL Insider Trading

Insider Ownership Percentage: 11.40%
Insider Buying (Last 12 Months): $32,919.40
Insider Selling (Last 12 Months): $0.00

Anavex Life Sciences Insider Trading History Chart

This chart shows the insider buying and selling history at Anavex Life Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$2M-$1M$0$1M$2MTotal Insider BuyingTotal Insider Selling

Anavex Life Sciences Share Price & Price History

Current Price: $8.55
Price Change: Price Increase of +0.3 (3.64%)
As of 05/12/2025 05:00 PM ET

This chart shows the closing price history over time for AVXL up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JunJulAugSepOctNovDecJanFebMarAprMay$8.55Closing price on 05/12/25:

Anavex Life Sciences Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for Anavex Life Sciences (NASDAQ:AVXL)

31.55% of Anavex Life Sciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at AVXL by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$15Mbought$1.56MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$20M$0$20MTotal InflowsTotal Outflows
Anavex Life Sciences logo
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Read More on Anavex Life Sciences

Today's Range

Now: $8.55
Low: $8.40
High: $8.68

50 Day Range

MA: $8.93
Low: $7.60
High: $9.93

52 Week Range

Now: $8.55
Low: $3.51
High: $14.44

Volume

735,040 shs

Average Volume

1,218,090 shs

Market Capitalization

$729.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82

Who are the company insiders with the largest holdings of Anavex Life Sciences?

Anavex Life Sciences' top insider shareholders include:
  1. Christopher U Missling (CEO)
  2. Peter DO Donhauser (Director)
  3. Steffen Thomas (Director)
Learn More about top insider investors at Anavex Life Sciences.

Who are the major institutional investors of Anavex Life Sciences?

Anavex Life Sciences' top institutional shareholders include:
  1. Vanguard Group Inc. — 5.74%
  2. Nwam LLC — 1.17%
  3. Charles Schwab Investment Management Inc. — 0.78%
  4. Invesco Ltd. — 0.65%
  5. LPL Financial LLC — 0.64%
  6. Cambridge Investment Research Advisors Inc. — 0.29%
Learn More about top institutional investors of Anavex Life Sciences stock.

Which major investors are selling Anavex Life Sciences stock?

In the previous quarter, AVXL stock was sold by these institutional investors:
  1. Virtu Financial LLC
  2. Invesco Ltd.
  3. Alps Advisors Inc.
  4. Saxon Interests Inc.
  5. Charles Schwab Investment Management Inc.
  6. Prairiewood Capital LLC
  7. Envestnet Asset Management Inc.
  8. Deutsche Bank AG

Which major investors are buying Anavex Life Sciences stock?

In the last quarter, AVXL stock was acquired by institutional investors including:
  1. LPL Financial LLC
  2. Vanguard Group Inc.
  3. Nuveen LLC
  4. Private Advisor Group LLC
  5. Cambridge Investment Research Advisors Inc.
  6. Swiss National Bank
  7. Apella Capital LLC
  8. Nwam LLC
Within the previous year, these company insiders have bought Anavex Life Sciences stock:
  1. Christopher U Missling (CEO)
  2. Peter DO Donhauser (Director)
Learn More investors buying Anavex Life Sciences stock.